Tizanidine Hydrochloride Capsule
Product Images NDC 80425-0448

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Tizanidine Hydrochloride (NDC 80425-0448). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Advanced Rx Of Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Tizanidine HCl 6mg Capsule #30 (Tizanidine HCl 6mg 80425 0448 01)

Label for Tizanidine HCl 6 mg capsules by Advanced Rx of Tennessee, LLC. The label includes NDC 80425-0448-01 and a source NDC 50742-0226-15. It references a comparison to Zanaflex and states a lot number and expiration date of 7/31/2027. The label also includes storage instructions at 20°-25°C and cautions about prescription transfer.*

FDA Label Image

Tizanidine HCl 6mg Capsule #60 (Tizanidine HCl 6mg 80425 0448 02)

Label for Tizanidine HCl 6 mg capsule by Advanced Rx of Tennessee, LLC. It includes storage instructions (20-25°C), patient prescription use caution, QR code, and barcode. The label references NDC 80425-0448-02, source NDC 50742-0226-15, lot and expiration placeholders, and indicates the product is Rx only.*

FDA Label Image

Tizanidine HCl 6mg Capsule #90 (Tizanidine HCl 6mg 80425 0448 03)

Label for Tizanidine Hydrochloride 6 mg capsule by Advanced Rx of Tennessee, LLC, NDC 80425-0448. It includes storage instructions, a comparison note to another drug (Zanaflex), lot and expiration dates, and barcodes. The label states 'Rx Only' and the capsule is identified by number 90.*

FDA Label Image

Tizanidine Structure (Fe05ad15 Db11 4d9e 9fb8 721cec4633d9 01)

Chemical structure of tizanidine hydrochloride. The diagram shows a molecular formula featuring a chlorinated benzene ring fused with a thiazole ring and connected to a substituted imidazoline group, including an HCl component indicating the hydrochloride salt form.*

FDA Label Image

Figure 1 (Fe05ad15 Db11 4d9e 9fb8 721cec4633d9 02)

A pharmacokinetic graph showing plasma concentration of tizanidine over 24 hours after dosing. The plot compares four conditions: 2 x 4 mg tizanidine tablets with food, without food, 2 x 4 mg tizanidine capsules with food, and without food, illustrating their effects on plasma tizanidine levels over time.*

FDA Label Image

Figure 2 (Fe05ad15 Db11 4d9e 9fb8 721cec4633d9 03)

A line graph illustrating improvement in Ashworth Score over 6 hours post-dose for three groups: 16 mg tizanidine, 8 mg tizanidine, and placebo. The y-axis shows improvement scores ranging from 1 to -5; the x-axis shows time from 0 to 6 hours. The 16 mg dose shows the greatest improvement peak at 2 hours, followed by the 8 mg dose and placebo with less improvement.*

FDA Label Image

Figure 3 (Fe05ad15 Db11 4d9e 9fb8 721cec4633d9 04)

A line graph depicting improvement in Ashworth Score over time in three study phases: End of Titration (Week 3), End of Maintenance (Week 7), and Endpoint (Last Observation Carried Forward). Two groups are compared: tizanidine (mean dose 28.8 mg) showing marked improvement, and placebo showing minimal change, with error bars for variability.*

FDA Label Image

Image (Fe05ad15 Db11 4d9e 9fb8 721cec4633d9 143 1)

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.